AVCT Stock Overview
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Avacta Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.45 |
| 52 Week High | UK£1.67 |
| 52 Week Low | UK£0.43 |
| Beta | 1.2 |
| 1 Month Change | -11.59% |
| 3 Month Change | -55.22% |
| 1 Year Change | -64.29% |
| 3 Year Change | -82.53% |
| 5 Year Change | 42.86% |
| Change since IPO | -88.61% |
Recent News & Updates
Recent updates
Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding
Feb 23
Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely
Aug 05Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?
Jun 22We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely
Oct 20This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation
Jun 22Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans
Jun 20Avacta Group Plc (LON:AVCT) Insiders Have Been Selling
Feb 18Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth
Jan 23
What Kind Of Shareholders Hold The Majority In Avacta Group Plc's (LON:AVCT) Shares?
Dec 27How Is Avacta Group's (LON:AVCT) CEO Paid Relative To Peers?
Dec 06Shareholder Returns
| AVCT | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.3% | -0.4% | 2.2% |
| 1Y | -64.3% | -29.1% | 0.9% |
Return vs Industry: AVCT underperformed the UK Biotechs industry which returned -29.5% over the past year.
Return vs Market: AVCT underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| AVCT volatility | |
|---|---|
| AVCT Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AVCT's share price has been volatile over the past 3 months.
Volatility Over Time: AVCT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 120 | David Alastair Smith | www.avacta.com |
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms.
Avacta Group Plc Fundamentals Summary
| AVCT fundamental statistics | |
|---|---|
| Market cap | UK£159.86m |
| Earnings (TTM) | -UK£42.08m |
| Revenue (TTM) | UK£16.03m |
10.0x
P/S Ratio-3.8x
P/E RatioIs AVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCT income statement (TTM) | |
|---|---|
| Revenue | UK£16.03m |
| Cost of Revenue | UK£8.36m |
| Gross Profit | UK£7.67m |
| Other Expenses | UK£49.75m |
| Earnings | -UK£42.08m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 47.85% |
| Net Profit Margin | -262.60% |
| Debt/Equity Ratio | 198.6% |
How did AVCT perform over the long term?
See historical performance and comparison